相关实验视频
Updated: Sep 10, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
在怀孕期间使用先进技术治疗1型糖尿病
Ina Geerts1, Katrien Benhalima2
1Clinical and Experimental Endocrinology, KU Leuven, Belgium.
自动注射胰岛素 (AID) 系统可以改善1型糖尿病孕妇的血糖控制. 研究表明,在分娩和产后使用的范围和安全性增加了,但对母亲/新生儿的结果需要进一步调查.
科学领域:
- 内分泌学
- 生殖医学
- 医疗技术
背景情况:
- 自动注射胰岛素 (AID) 系统已经改变了1型糖尿病的治疗.
- 越来越多的艾滋病预孕需要了解其在怀孕期间的作用.
- 关于AID在孕妇中有效性和安全性的数据有限.
研究的目的:
- 审查目前关于AID系统在怀孕和产后的有效性和安全性的证据.
- 评估AID对1型糖尿病孕妇血糖控制的影响.
- 探讨艾滋病对母亲和新生儿的潜在益处.
主要方法:
- 随机对照试验 (RCT) 的综述和近期关于孕妇使用抗胰岛素的数据.
- 分析涉及特定AID系统的研究,如CamAPS® FX和MiniMedTM 780G.
- 在分娩和产后期间检查安全数据.
主要成果:
- 与标准治疗相比,一个大型RCT显示CamAPS® FX的范围时间增加了10%.
- CamAPS® FX是唯一被批准用于怀孕的辅助系统.
- 与标准胰岛素治疗相比,MiniMedTM 780G系统也显示出一些好处.
- 在分娩期间和分娩后继续使用AID似乎是安全的.
结论:
- 艾滋病系统有望改善1型糖尿病孕妇的血糖控制.
- 目前的证据支持在分娩和产后继续使用AID的安全性.
- 需要进一步的研究来确定AID是否改善孕产妇和新生儿的结果.
更多相关视频
08:16Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
Published on: March 15, 2024
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...